|
Immunity, Cellular
|
D007111 |
[Manifestations of the immune response which are mediated by antigen-sensitized T-lymphocytes via lymphokines or direct cytotoxicity. This takes place in the absence of circulating antibody or where antibody plays a subordinate role.
] |
|
Immunity, Herd
|
D032521 |
[The non-susceptibility to infection of a large group of individuals in a population. A variety of factors can be responsible for herd immunity and this gives rise to the different definitions used in the literature. Most commonly, herd immunity refers to the case when, if most of the population is immune, infection of a single individual will not cause an epidemic. Also, in such immunized populations, susceptible individuals are not likely to become infected. Herd immunity can also refer to the case when unprotected individuals fail to contract a disease because the infecting organism has been banished from the population.
] |
|
Immunity, Heterologous
|
D064789 |
[The immunological phenomenon by which exposure to some organisms or vaccines can profoundly alter the host's response to subsequent exposure to unrelated (heterologous) organisms or vaccines.
] |
|
Immunity, Humoral
|
D056724 |
[Antibody-mediated immune response. Humoral immunity is brought about by ANTIBODY FORMATION, resulting from TH2 CELLS activating B-LYMPHOCYTES, followed by COMPLEMENT ACTIVATION.
] |
|
Immunity, Innate
|
D007113 |
[The capacity of a normal organism to remain unaffected by microorganisms and their toxins. It results from the presence of naturally occurring ANTI-INFECTIVE AGENTS, constitutional factors such as BODY TEMPERATURE and immediate acting immune cells such as NATURAL KILLER CELLS.
] |
|
Immunity, Maternally-Acquired
|
D007112 |
[Resistance to a disease-causing agent induced by the introduction of maternal immunity into the fetus by transplacental transfer or into the neonate through colostrum and milk.
] |
|
Immunity, Mucosal
|
D018928 |
[Nonsusceptibility to the pathogenic effects of foreign microorganisms or antigenic substances as a result of antibody secretions of the mucous membranes. Mucosal epithelia in the gastrointestinal, respiratory, and reproductive tracts produce a form of IgA (IMMUNOGLOBULIN A, SECRETORY) that serves to protect these ports of entry into the body.
] |
|
Immunization
|
D007114 |
[Deliberate stimulation of the host's immune response. ACTIVE IMMUNIZATION involves administration of ANTIGENS or IMMUNOLOGIC ADJUVANTS. PASSIVE IMMUNIZATION involves administration of IMMUNE SERA or LYMPHOCYTES or their extracts (e.g., transfer factor, immune RNA) or transplantation of immunocompetent cell producing tissue (thymus or bone marrow).
] |
|
Immunization Programs
|
D017589 |
[Organized services to administer immunization procedures in the prevention of various diseases. The programs are made available over a wide range of sites: schools, hospitals, public health agencies, voluntary health agencies, etc. They are administered to an equally wide range of population groups or on various administrative levels: community, municipal, state, national, international.
] |
|
Immunization Schedule
|
D007115 |
[Schedule giving optimum times usually for primary and/or secondary immunization.
] |
|
Immunization, Passive
|
D007116 |
[Transfer of immunity from immunized to non-immune host by administration of serum antibodies, or transplantation of lymphocytes (ADOPTIVE TRANSFER).
] |
|
Immunization, Secondary
|
D007117 |
[Any immunization following a primary immunization and involving exposure to the same or a closely related antigen.
] |
|
Immunoassay
|
D007118 |
[A technique using antibodies for identifying or quantifying a substance. Usually the substance being studied serves as antigen both in antibody production and in measurement of antibody by the test substance.
] |
|
Immunoblastic Lymphadenopathy
|
D007119 |
[A disorder characterized by proliferation of arborizing small vessels, prominent immunoblastic proliferations and amorphous acidophilic interstitial material. Clinical manifestations include fever, sweats, weight loss, generalized lymphadenopathy and frequently hepatosplenomegaly.
] |
|
Immunoblotting
|
D015151 |
[Immunologic method used for detecting or quantifying immunoreactive substances. The substance is identified by first immobilizing it by blotting onto a membrane and then tagging it with labeled antibodies.
] |
|
Immunochemistry
|
D007120 |
[Field of chemistry that pertains to immunological phenomena and the study of chemical reactions related to antigen stimulation of tissues. It includes physicochemical interactions between antigens and antibodies.
] |
|
Immunocompetence
|
D007121 |
[The ability of lymphoid cells to mount a humoral or cellular immune response when challenged by antigen.
] |
|
Immunocompromised Host
|
D016867 |
[A human or animal whose immunologic mechanism is deficient because of an immunodeficiency disorder or other disease or as the result of the administration of immunosuppressive drugs or radiation.
] |
|
Immunoconglutinins
|
D037561 |
[Autoantibodies directed against newly-formed EPITOPES created as the COMPLEMENT cascade is activated and the proteins involved change their conformations.
] |
|
Immunoconjugates
|
D018796 |
[Combinations of diagnostic or therapeutic substances linked with specific immune substances such as IMMUNOGLOBULINS; MONOCLONAL ANTIBODIES; or ANTIGENS. Often the diagnostic or therapeutic substance is a radionuclide. These conjugates are useful tools for specific targeting of DRUGS and RADIOISOTOPES in the CHEMOTHERAPY and RADIOIMMUNOTHERAPY of certain cancers.
] |
